Form 10-Q Evoke Pharma Inc For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Noble Financial Keeps Evoke Pharma (EVOK) at 'Hold' Following Q2 Numbers; Still Awaiting Development Plans
August 16, 2016 8:43 AM EDTNoble Financial affirms Evoke Pharma (Nasdaq: EVOK) with a Hold rating following Q2 results issued Monday night.
Analyst Nathan Cali noted the following on Tuesday:
Operational costs incrementally lower. August 15th, 2016, reported second quarter financial results; no revenues as expected; SG&A $802,655... MoreEvoke Pharma (EVOK) Tops Q2 EPS by 2c
August 15, 2016 4:35 PM EDTEvoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43).
As of June 30, 2016, the Company's cash and cash equivalents were approximately $4.1 million.
Dave Gonyer, R.Ph., President and CEO, stated, Following the results of our recently concluded Phase 3 study of Gimoti, our nasally delivered metoclopramide product for the treatment of diabetic gastroparesis in women, we continue to analyze the incoming data to further understand the... More
